Large-scale capital investment in the Maebashi Research Institute and pilot plant
First written in FY2016. 2 of 13 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Capital expenditures declined, with no significant new investment plansAnnual report
「Total capital expenditures on property, plant and equipment during the consolidated fiscal year were ¥40.066 million, including property, plant and equipment under construction. The expenditures were as follows:」
¥40.066 million was invested in manufacturing- and development-related equipment and other items at the Fujioka, Maebashi and Mikasa research institutes. This was down from ¥70.259 million in the previous year, and there are no significant capital investment plans for the following fiscal year. - FY2026-H1Equipment acquired in the first halfAnnual report
「The main factor was expenditure of ¥28.924 million on the acquisition of property, plant and equipment, among other items.」
During the interim consolidated accounting period, property, plant and equipment was acquired, and ¥28.924 million was spent on equipment acquisitions in investing activities. - FY2025Investment in solar power generation and manufacturing equipment implementedAnnual report
「Total capital expenditures on property, plant and equipment during the consolidated fiscal year were ¥70.259 million, comprising the following: ・Fujioka Research Institute: solar power generation equipment, manufacturing-related equipment and other items (antibody-related business) ・Maebashi Research Institute: manufacturing-related equipment and other items (antibody-related business)」
Capital expenditures increased from ¥22.958 million in the previous fiscal year to ¥70.259 million, with solar power generation and manufacturing-related equipment acquired for the Fujioka Research Institute and manufacturing-related equipment acquired for the Maebashi Research Institute. - FY2025-H1Equipment acquired in the first halfAnnual report
「The main factors were a ¥12.189 million decrease in trade receivables, a ¥7.918 million increase in deferred tax assets and a ¥31.520 million increase resulting from the acquisition of property, plant and equipment.」
During the interim consolidated accounting period, the carrying amount increased by ¥31.520 million due to the acquisition of property, plant and equipment, and ¥35.161 million was spent on equipment acquisitions in investing activities. Meanwhile, the major facilities section stated that there were no applicable items. - FY2024Fixed asset investment resumed, but there are no significant new investment plansAnnual report
「Total capital expenditures on property, plant and equipment during the consolidated fiscal year were ¥22.958 million. The expenditures were as follows: ・Fujioka Research Institute: manufacturing-related equipment, server equipment and other items (antibody-related business)」
Capital expenditures increased from none in the previous fiscal year to ¥22.958 million, mainly for manufacturing-related equipment, server equipment and other items at the Fujioka Research Institute. There are no significant capital investment plans for the following fiscal year. - FY2023No capital expenditures on property, plant and equipment during the fiscal yearAnnual report
「There were no capital expenditures on property, plant and equipment during the consolidated fiscal year.」
Following the large-scale investment in the Maebashi Research Institute and elsewhere, no capital expenditures on property, plant and equipment were made during the fiscal year, and there were no significant plans for new facilities or disposals. - FY2021Small-scale capital expenditures implementedAnnual report
「Total capital expenditures on property, plant and equipment during the consolidated fiscal year were ¥13.460 million, comprising ¥13.431 million for the diagnostics and reagents business, ¥22 thousand for the genetically modified silkworm business and ¥6 thousand for the testing business. The expenditures were for business-use land at the Fujioka Research Institute.」
Following the large-scale capital investment in the Maebashi Research Institute, capital expenditures during the fiscal year were limited to ¥13.460 million, mainly for business-use land at the Fujioka Research Institute, with no significant new investment plans. - FY2018No capital expenditures during the fiscal yearAnnual report
「There were no capital expenditures on property, plant and equipment during the consolidated fiscal year.」
Following completion of the Maebashi Research Institute and pilot plant, there were no capital expenditures on property, plant and equipment during the consolidated fiscal year, and no significant new capital investment plans were disclosed. - FY2017RestatedAnnual report
「During the consolidated fiscal year, a pilot plant was established in Maebashi, Gunma Prefecture, as a base for the genetically modified silkworm business, and operations commenced as the Maebashi Research Institute.」
The establishment and commencement of operations of the Maebashi Research Institute and pilot plant were reconfirmed. - FY2017-Q3RestatedAnnual report
「In the genetically modified silkworm business, the GMP pilot production facility for proteins produced by genetically modified silkworms was completed in August 2016 and opened as the Maebashi Research Institute. Capital expenditures totaled ¥1,040.062 million.」
The completion of the Maebashi Research Institute and GMP pilot production facility was reconfirmed, and capital expenditures were disclosed as ¥1,040.062 million. - FY2017-Q2AdvancedAnnual report
「Property, plant and equipment increased by ¥320.084 million due to the establishment of the new Maebashi Research Institute and other factors」
Construction of the new Maebashi Research Institute progressed, increasing property, plant and equipment by ¥320.084 million. Capital expenditures for the GMP pilot production facility were ¥1,038.564 million. - FY2017-Q1AdvancedAnnual report
「Property, plant and equipment under construction increased by ¥52.252 million as the new Maebashi Research Institute was established」
Construction of the new Maebashi Research Institute progressed, increasing property, plant and equipment under construction by ¥52.252 million. - FY2016First statedAnnual report
「Total capital expenditures on property, plant and equipment during the consolidated fiscal year were ¥707.404 million. Capital expenditures by segment were as follows:」
¥687.788 million was invested in the genetically modified silkworm business, and construction of a pilot plant at the Maebashi Research Institute is under way.